StreetInsider.com News Articles

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

Mon, 12 Oct 2026 16:05:00 -0400

-- Company to Host Learning Theatre on aPAP with Renowned Key Opinion Leader Along with Members of the Patient Community --

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an encore oral presentation on data from the Phase 3 IMPALA-2 clinical trial and a poster presentation on data from the Phase 2/3 IMPALA clinical trial at CHEST 2026 in Phoenix, Arizona, October 18–21.

Oral Presentation

Title: Long-Term Efficacy and Safety of Molgramostim in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

Mon, 12 Oct 2026 16:05:00 -0400

-- Company to Host Learning Theatre on aPAP with Renowned Key Opinion Leader Along with Members of the Patient Community --

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an encore oral presentation on data from the Phase 3 IMPALA-2 clinical trial and a poster presentation on data from the Phase 2/3 IMPALA clinical trial at CHEST 2026 in Phoenix, Arizona, October 18–21.
Oral Presentation
Title: Long-Term Efficacy and Safety of Molgramostim in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results

JPMorgan Starts Savara (SVRA) at Overweight

Wed, 07 Oct 2026 05:15:10 -0400

JPMorgan initiates coverage on Savara (NASDAQ: SVRA) with a Overweight rating and a price target of $12.00.

For an analyst ratings summary and ratings history on Savara click here. For more ratings news on Savara click here.

Shares of Savara closed at $4.65 yesterday.

Savara (SVRA) Reiterated at Market Outperform by Citizens on Molbreevi Optimism

Wed, 07 Oct 2026 04:35:41 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $10.00 price target on Savara (NASDAQ: SVRA).
The analyst commented, "Looking back at historical pulmonary launches and Savara’s commercial prep makes us optimistic for Molbreevi to top expectations in both the near and long term; we reiterate our Market Outperform rating and $10 risk-adjusted, DCF-derived price target on Savara. Key Points: Molbreevi’s November 22 PDUFA is fast approaching, where we think approval is likely (90% POS) and believe investor attention is turning toward launch expectations. With a line of sight to ~1,000+ patients, a high expectation to treat from pulmonologists, and

Form 4 Savara Inc For: Sep 24 Filed by: Parker Braden C.

Fri, 25 Sep 2026 19:02:00 -0400
si-local-file:///var/storage/secattach/20260925/27108413.html

Increasing unusual call option volume: BBD SVRA SGHC ABUS XP U GDDY ACAD AUPH TSSI LTH

Fri, 25 Sep 2026 06:06:45 -0400

Increasing unusual call option volume: BBD SVRA SGHC ABUS XP U GDDY ACAD AUPH TSSI LTH

Savara to present IMPALA-2 trial data at ERS Congress in Barcelona

Mon, 24 Aug 2026 16:05:47 -0400

Savara Inc. (Nasdaq: SVRA) announced that one oral presentation and two poster presentations on data from its Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution will be featured at the European Respiratory Society (ERS) Congress in Barcelona, Spain, from September 5–9, 2026.

The presentations focus on molgramostim, an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease with no currently approved pharmacologic treatments.

The oral presentation, scheduled for September 6, will cover long-term efficacy and safety results from the open-label period of the IMPALA-2 trial, including data through 48 weeks. It

Savara to present IMPALA-2 trial data at ERS Congress in Barcelona

Mon, 24 Aug 2026 16:05:47 -0400

Savara Inc. (Nasdaq: SVRA) announced that one oral presentation and two poster presentations on data from its Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution will be featured at the European Respiratory Society (ERS) Congress in Barcelona, Spain, from September 5–9, 2026.

The presentations focus on molgramostim, an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease with no currently approved pharmacologic treatments.

The oral presentation, scheduled for September 6, will cover long-term efficacy and safety results from the open-label period of the IMPALA-2 trial, including data through 48 weeks. It

Savara to present IMPALA-2 trial data at ERS Congress in Barcelona

Mon, 24 Aug 2026 16:05:47 -0400

Savara Inc. (Nasdaq: SVRA) announced that one oral presentation and two poster presentations on data from its Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution will be featured at the European Respiratory Society (ERS) Congress in Barcelona, Spain, from September 5–9, 2026.

The presentations focus on molgramostim, an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease with no currently approved pharmacologic treatments.

The oral presentation, scheduled for September 6, will cover long-term efficacy and safety results from the open-label period of the IMPALA-2 trial, including data through 48 weeks. It

Savara to present IMPALA-2 trial data at ERS Congress in Barcelona

Mon, 24 Aug 2026 16:05:47 -0400

Savara Inc. (Nasdaq: SVRA) announced that one oral presentation and two poster presentations on data from its Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution will be featured at the European Respiratory Society (ERS) Congress in Barcelona, Spain, from September 5–9, 2026.

The presentations focus on molgramostim, an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease with no currently approved pharmacologic treatments.

The oral presentation, scheduled for September 6, will cover long-term efficacy and safety results from the open-label period of the IMPALA-2 trial, including data through 48 weeks. It

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European

Mon, 24 Aug 2026 16:05:00 -0400

-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European

Mon, 24 Aug 2026 16:05:00 -0400

-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European

Mon, 24 Aug 2026 16:05:00 -0400

-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European

Mon, 24 Aug 2026 16:05:00 -0400

-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European

Mon, 24 Aug 2026 16:05:00 -0400

-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European

Mon, 24 Aug 2026 16:05:00 -0400

-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European

Mon, 24 Aug 2026 16:05:00 -0400

-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European

Mon, 24 Aug 2026 16:05:00 -0400

-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may

Savara Announces New Employment Inducement Grant

Thu, 20 Aug 2026 16:05:00 -0400

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees.
On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company’s common stock and restricted stock units (RSUs) covering 64,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan

Savara Announces New Employment Inducement Grant

Thu, 20 Aug 2026 16:05:00 -0400

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees.
On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company’s common stock and restricted stock units (RSUs) covering 64,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan

Savara Announces New Employment Inducement Grant

Thu, 20 Aug 2026 16:05:00 -0400

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees.
On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company’s common stock and restricted stock units (RSUs) covering 64,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan

Savara Announces New Employment Inducement Grant

Thu, 20 Aug 2026 16:05:00 -0400

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees.
On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company’s common stock and restricted stock units (RSUs) covering 64,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan

Form SCHEDULE 13G/A Savara Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Fri, 14 Aug 2026 08:23:00 -0400
si-local-file:///var/storage/secattach/20260814/26925035.html

Form SCHEDULE 13G/A Savara Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Fri, 14 Aug 2026 08:23:00 -0400
si-local-file:///var/storage/secattach/20260814/26925035.html

Form S-8 Savara Inc

Tue, 11 Aug 2026 17:12:00 -0400
si-local-file:///var/storage/secattach/20260811/26907000.html